Abstract 107: Application of MSD on the lung cancer associated idiopathic pulmonary fibrosis

Abstract

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible chronic disease that kill ten thousand of people in China every year. The risk of IPF is highly correlated with smoke, air pollution, dust, virus infection and aging. Average survival period of patients diagnosed as IPF is around 2.8 years which is less than several types of cancers, therefore, IPF is also thought to be a lung cancer-like disease. In the past few decades, many animal models were created to mimic human IPF, however, induction materials, animal species and strain differences, sex, physiology structure and progress of disease make the choice of IPF animal models selection more difficult. In addition, lack of strong evidence of cytokines biomarker detection hampered the discovery of anti-IPF drugs. Meso Scale Discovery (MSD) instrument is an efficient tool to high throughput analyze the lowest level of several cytokines and other biomarkers in the same time and was used to detect the bleomycin (BLM) induced mouse lung fibrosis. Meanwhile, animal sex and dose effects of BLM were also tested to define the proper mouse model for anti-IPF drugs development. Our results indicated that 0.6-0.8 mg/kg of intratracheal injection of single dose BLM is sufficient to create the IPF model without sex differences by examining the lung weight, lung ratio, soluble hydroxyproline, HE staining and mason staining. However, male mice were more resistant to the lethal effect of BLM due to the larger size or bodyweight. Using MSD detection, several mouse cytokines were measured simultaneously and showed that IFN-γ, IL-5, TNF-α, and IL-10 were increased in the IPF mouse model and were recovered after pirfenidone treatment at day 14 which mimics the cytokines profile in IPF patients. In summary, the MSD detection and pathological evaluation prove that male mouse treated with 0.8 mg/kg BLM through intratracheal injection is a suitable mouse model for the development of anti-IPF dugs. Citation Format: Wei Bao, Ying-Ji Li, Jin-Fan Gu, Cong-Lin Yang, Yi-Da Wang, Tie-Jun Bing, Wen-Jen Yu. Application of MSD on the lung cancer associated idiopathic pulmonary fibrosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 107.